Novo Nordisk pauses trials in haemophilia A and B - Nordic Life Science – the leading Nordic life science news service
Novo Nordisk (NOVO-B) hit by drop in insulin sales in China
Novo Nordisk's Ozempic Receives the US FDA's Approval for the Treatment of Type 2 Diabetes
ar_001.jpg
Novo to buy Forma Therapeutics for $1.1B - News
Novo-Nordisk B dividend yield
Corvidia Therapeutics is sold to Novo for $2.1B | 2020-06-11 | BioWorld
Novo Nordisk, underway with key launches, reveals $2.58B manufacturing investment | Fierce Pharma
Novo Nordisk Foundation - Wikipedia
Novo Nordisk - Home | Facebook
With new FDA submission, Novo Nordisk aims to trumpet Tresiba's hypoglycemia edge | Fierce Pharma
Drugmaker Novo Nordisk profits jump in diabetes scourge
Novo Nordisk's long-acting haemophilia B drug cleared by FDA - PMLiVE
Novo Nordisk to Sell Discount Insulin After Criticism Over Price - Bloomberg
Lene B. Oddershede to head Novo Nordisk Foundation's grants for research in the natural and technical sciences - Novo Nordisk Fonden
Rejected Again: Ablynx Turns Down Novo Nordisk's Sweetened $3.1B Bid | BioSpace
Novo Nordisk CEO: Very upbeat on outlook for 2022
Novo Nordisk A/S Stock Forecast: up to 1198.365 DKK! - NOVO-B Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis
